- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02615847
Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients (MemSID)
A Phase II, Open Label, Single Center Trial to Study the Safety and Tolerability of Memantin Mepha® as Supportive Long Term Treatment in Symptomatic Sickle Cell Disease
Symptomatic sickle cell disease is worldwide the most frequent cause for hereditary hemolytic anemia with recurrent pain crisis. Hemolysis, vaso- occlusive and pain crises are hallmarks of this disease and are causative for an important socio-economic burden worldwide, especially in Africa.
Aside from allogenic stem cell transplantation, which is rarely available and very expensive, at present there is no curative treatment for patients with sickle cell disease (SCD). The current standard of care includes treatment with hydroxycarbamide and symptomatic care such as transfusions, antibiotic/analgesic treatment.
This study has the aim to study the safety and tolerability of Memantin in patients with sickle cell disease.
Panoramica dello studio
Descrizione dettagliata
During the study participants will be asked if medical occurrences (AEs) happened and laboratory analysis (haematology, coagulation, chemistry) and urine samples will be taken. In addition at each visit a physical examination and measurement of vital signs will be performed.
In addition the number of hospital days and emergency consultations, the impact on working ability (the number of days with inability to work, changes in iv%), the amount and type of analgesic medication, the amount of RBC transfusions, the number of days that antibiotics prescribed and haematology (at local and external laboratory) and chemistry laboratory parameters will be assessed. For the impact on work and social life a questionnaire of quality of life will be filled out monthly by the patient.
At screening and at the end of the study SCD specific assessments will be performed, which include cardiologic examination (ECG, ECHO), abdominal sonography, ophthalmological examination, lung function testing and neuroangiologic examination.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Zürich, Svizzera, 8091
- University Hospital Zurich
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Documented symptomatic sickle cell disease (HbSS or HbS/beta thalassemia)
- Age 18 years or older
- Able and willing to provide written informed consent and to comply with the study protocol procedures
- Willing to use two effective methods of contraception during study treatment until 6 months after stop of study treatment. Effective contraception methods are considered oral, injectable, implantative contraceptives or intrauterine contraceptive devices combined with the use of condom.
Exclusion Criteria:
History of transfusion during last three months before Screening
- Patients with active bacterial, viral or fungal infection requiring systemic treatment
- Patients with known infection with human immunodeficiency virus (HIV) of human T cell leukaemia virus 1 (HTLV-1)
- Inadequate renal function: creatinine clearance < 30ml/min
- Inadequate liver function: NCICTC Grade 3 liver function tests (AST, ALT > 5x upper limit of normal (ULN))
- History of malignancy
- Women who are pregnant or breast feeding
- Previous known mental disorder or known family history of psychiatric diseases
- Known epileptic disease
- The receipt of any investigational product within 30 days prior to this trial
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Memantin arm
Memantinhydrochlorid, administered once per day during 12 month.
Dosage is from 0-20 mg.
|
Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister. The study drug will be taken once a day per os, during 12 month.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Number of participants with treatment related adverse events as assessed by CTCAE version 4.0
Lasso di tempo: 14 month
|
14 month
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Haemoglobin in g/l
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Erythrocytes in T/l
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Reticulocytes in G/l
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Haptoglobin in g/l
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Billirubin in micmol/l
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
LDH (Lactat dehydrogenase) in U/l
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Ferritin in micg/l
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Transferrin saturation in %
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days in hospital
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days with inability to work
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of transfusions
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days taken antibiotics
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Amount of pain medication in mg or ml
Lasso di tempo: 38 month
|
2 years before screening until end of study.
|
38 month
|
Pain scale
Lasso di tempo: 38 month
|
Scores range from 0 (no pain) to 10 (worst possible pain).
|
38 month
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: Jeroen Goede, MD, UniversitätsSpital Zürich
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HbSS-MemSID
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Anemia falciforme
-
Genentech, Inc.ReclutamentoMelanoma | Cancro cervicale | HCC | Tumore gastrico | Cancro esofageo | NSCLC | Carcinoma uroteliale | HNSCC | Tumori solidi localmente avanzati o metastatici | TNBC | Clear Cell RCCCorea, Repubblica di, Olanda, Spagna, Stati Uniti, Australia, Canada, Belgio
-
The Netherlands Cancer InstitutePfizerReclutamentoCarcinoma a cellule renaliOlanda
-
National Cancer Centre, SingaporeTerminatoLINFOMA EXTRANODALE NK-T-CELLSingapore
-
Medical College of WisconsinUniversity of Wisconsin, Madison; AmgenReclutamentoLeucemia linfoblastica acuta a cellule B | Leucemia linfoblastica acuta infantile a cellule B | B-Cell ALL, InfanziaStati Uniti
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group BCompletatoCarcinoma a cellule renali a cellule chiare | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti, Canada, Porto Rico
-
National Cancer Institute (NCI)TerminatoCarcinoma a cellule renali a cellule chiare | Carcinoma a cellule renali metastatico | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio IV AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti
-
Peloton Therapeutics, Inc., a subsidiary of Merck...National Institutes of Health (NIH)CompletatoCarcinoma a cellule renali a cellule chiare | Malattia di Von Hippel-Lindau | Clear Cell RCC | ccRCC | Mutazione del gene VHL | Sindrome VHL | Inattivazione del gene VHL | VHL | Von Hippel | Malattia di Von Hippel | Sindrome di von Hippel-Lindau, modificatori diStati Uniti